Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epidermal Growth Factor Receptor targeting in non-small cell lung cancer: revisiting different strategies against the same target.

Current drug targets - 1 Jan 2014

Castañón Eduardo, Martín Patricia, Rolfo Christian, Fusco Juan P, Ceniceros Lucía, Legaspi Jairo, Santisteban Marta, Gil-Bazo Ignacio

Abstract excerpt

Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) have changed the paradigm of treatment in non-small cell lung cancer (NSCLC). The molecular biology study of EGFR has led to clinical trials that select patients more accurately, regarding the presence of EGFR activating mutations. Nonetheless, a lack of response or a temporary condition of the response has been detected in patients on EGFR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Drug Design

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 25511613
DOI: 10.2174/138945011514141216092935

Genes

EGFR
MET

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epidermal Growth Factor Receptor targeting in non-small cell lung cancer: revisiting different strategies against the same target.PMID 25511613Read ↗

EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?Semantic proximity Read ↗

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.Semantic proximity Read ↗

Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives.Semantic proximity Read ↗

Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A ReviewSemantic proximity Read ↗

EGFR-TKIs in non-small-cell lung cancer: focus on clinical pharmacology and mechanisms of resistance.Semantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer.Semantic proximity Read ↗

Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer.Semantic proximity Read ↗

Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies.Semantic proximity Read ↗

Review. EGFR mutations in non-small cell lung cancer--clinical implications.Semantic proximity Read ↗

Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib.Semantic proximity Read ↗

Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer.Semantic proximity Read ↗

Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.